Literature DB >> 11349050

Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo.

K Brahimi1, E Badell, J P Sauzet, L BenMohamed, P Daubersies, C Guérin-Marchand, G Snounou, P Druilhe.   

Abstract

The Plasmodium falciparum liver-stage antigen 3 (LSA3), a recently identified preerythrocytic antigen, induces protection against malaria in chimpanzees. Using antibodies from individuals with hyperimmunity to malaria affinity purified on recombinant or synthetic polypeptides of LSA3, we identified four non-cross-reactive B-cell epitopes in Plasmodium yoelii preerythrocytic stages. On sporozoites the P. yoelii protein detected has a molecular mass similar to that of LSA3. T-cell epitopes cross-reacting with P. yoelii were also demonstrated using peripheral blood lymphocytes from LSA3-immunized chimpanzees. In contrast, no cross-reactive epitopes were found in Plasmodium berghei. LSA3-specific human antibodies exerted up to 100% inhibition of in vitro invasion of P. yoelii sporozoites into mouse hepatocytes. This strong in vitro activity was reproduced in vivo by passive transfer of LSA3 antibodies. These results indicate that the homologous epitopes may be biologically functional and suggest that P. yoelii could be used as a model to assess the antisporozoite activity of anti-LSA3 antibodies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11349050      PMCID: PMC98406          DOI: 10.1128/IAI.69.6.3845-3952.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules.

Authors:  L Benmohamed; A Thomas; M Bossus; K Brahimi; J Wubben; H Gras-Masse; P Druilhe
Journal:  Vaccine       Date:  2000-06-15       Impact factor: 3.641

2.  Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

Authors:  J A Stoute; K E Kester; U Krzych; B T Wellde; T Hall; K White; G Glenn; C F Ockenhouse; N Garcon; R Schwenk; D E Lanar; P Sun; P Momin; R A Wirtz; C Golenda; M Slaoui; G Wortmann; C Holland; M Dowler; J Cohen; W R Ballou
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

3.  A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii.

Authors:  J M Burns; L A Parke; T M Daly; L A Cavacini; W P Weidanz; C A Long
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

4.  Immunization of man against sporozite-induced falciparum malaria.

Authors:  D F Clyde; H Most; V C McCarthy; J P Vanderberg
Journal:  Am J Med Sci       Date:  1973-09       Impact factor: 2.378

5.  Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies.

Authors:  M J Stewart; R J Nawrot; S Schulman; J P Vanderberg
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

6.  Levels of antibodies to Plasmodium falciparum sporozoite surface antigens reflect malaria transmission rates and are persistent in the absence of reinfection.

Authors:  P Druilhe; O Pradier; J P Marc; F Miltgen; D Mazier; G Parent
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

7.  Cloning of cDNAS that code for Plasmodium chabaudi antigens of the erythrocytic forms and cross-hybridize with P. falciparum.

Authors:  J Franco Da Silveira; L Sibilli; E Brunet; O Mercereau-Puijalon
Journal:  Mol Biochem Parasitol       Date:  1984-04       Impact factor: 1.759

8.  Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies.

Authors:  M R Hollingdale; E H Nardin; S Tharavanij; A L Schwartz; R S Nussenzweig
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

9.  Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.

Authors:  P Daubersies; A W Thomas; P Millet; K Brahimi; J A Langermans; B Ollomo; L BenMohamed; B Slierendregt; W Eling; A Van Belkum; G Dubreuil; J F Meis; C Guérin-Marchand; S Cayphas; J Cohen; H Gras-Masse; P Druilhe; L B Mohamed
Journal:  Nat Med       Date:  2000-11       Impact factor: 53.440

10.  Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro.

Authors:  D Mazier; S Mellouk; R L Beaudoin; B Texier; P Druilhe; W Hockmeyer; J Trosper; C Paul; Y Charoenvit; J Young
Journal:  Science       Date:  1986-01-10       Impact factor: 47.728

View more
  17 in total

Review 1.  Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design.

Authors:  Javier E Garcia; Alvaro Puentes; Manuel E Patarroyo
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

2.  Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine.

Authors:  T Scorza; K Grubb; P Smooker; A Rainczuk; D Proll; T W Spithill
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

3.  Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.

Authors:  Xiuli Zhang; Florence A Castelli; Xiaoming Zhu; Michele Wu; Bernard Maillère; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

4.  Liver stage antigen 3 isolated from a cDNA library of Plasmodium falciparum erythrocytic stages.

Authors:  Eva M Moyano; Luis Miguel González; Susana Arahuetes; Agustín Benito
Journal:  Parasitol Res       Date:  2007-09-09       Impact factor: 2.289

5.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

6.  Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.

Authors:  Lbachir BenMohamed; Georges Bertrand; Cory D McNamara; Helene Gras-Masse; Juergen Hammer; Steven L Wechsler; Anthony B Nesburn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3.

Authors:  Aissatou Toure-Balde; Blanca-Liliana Perlaza; Jean-Pierre Sauzet; Mouhamadou Ndiaye; Georgette Aribot; Adama Tall; Cheikh Sokhna; Christophe Rogier; Giampietro Corradin; Christian Roussilhon; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-01-12       Impact factor: 3.441

8.  Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum.

Authors:  Brandon K Sack; Jessica L Miller; Ashley M Vaughan; Alyse Douglass; Alexis Kaushansky; Sebastian Mikolajczak; Alida Coppi; Gloria Gonzalez-Aseguinolaza; Moriya Tsuji; Fidel Zavala; Photini Sinnis; Stefan H I Kappe
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

9.  Liver stage antigen 3 Plasmodium falciparum peptides specifically interacting with HepG2 cells.

Authors:  Javier E García; Hernando Curtidor; Ramses López; Luis Rodríguez; Ricardo Vera; John Valbuena; Jaiver Rosas; Marisol Ocampo; Alvaro Puentes; Martha Forero; Manuel A Patarroyo; Manuel Elkin Patarroyo
Journal:  J Mol Med (Berl)       Date:  2004-08-07       Impact factor: 4.599

10.  Co-infection of malaria and gamma-herpesvirus: exacerbated lung inflammation or cross-protection depends on the stage of viral infection.

Authors:  A Haque; N Rachinel; M R Quddus; S Haque; L H Kasper; E Usherwood
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.